Xavo proudly announces Plexium as its latest esteemed client. The collaboration between the two companies marks a significant milestone in Xavo’s journey.
While many pharmaceutical companies are chasing targeted and immunotherapy therapeutic drugs, protein degradation therapy has also attracted the attention of more and more companies and has become another new direction in the field of new drug R&D.
Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics...